• LPA regulates cytokines and cytokine decoy receptors release in lung epithelial cells.
Introduction
Lysophosphatidic acid (LPA) is a lysophospholipid, which has the simplest structure consisting of a long chain fatty acid linked to sn-1 or sn-2 and a phosphate group at sn-3 position of the glycerol backbone. LPA is a naturally occurring bioactive lysophospholipid present in most tissues and biological fluids at nM to μM concentrations. It plays a critical role in de novo biosynthesis of phospholipids and is also a key intermediate in the biosynthesis of phosphatidic acid (PA). Progress made over the past two decades has characterized LPA as a serum-derived growth factor that is involved in several cellular functions such as proliferation [1, 2] , migration [3, 4] , cytokine/chemokines secretion [5] [6] [7] , platelet aggregation [8, 9] , smooth muscle cell contraction [10] , and neurite retraction [11] . The biological effects of LPA are mediated through ligation to G protein-coupled LPA1-7 receptors expressed on the surface of variety of cells [12] [13] [14] . The cloning and characterization of LPA receptors have advanced our current understanding of LPA mediated signal transduction and biological responses in mammalian cells and tissues. Further, development of small molecular antagonists or agonists of LPA receptors, and genetically engineered LPA receptor(s) deficient mice has provided direct evidence supporting the various physiological and pathological roles of LPA and LPA receptors. Airway epithelial cells express predominantly LPA [1] [2] [3] and respond to exogenous LPA challenge by activation of transcriptional factors and cytokine secretion [6, 15, 16] . LPA and LPA receptors have been implicated in a number of human pathologies including cancer, fibrosis, reproductive disorders and bone metabolism (17, 18) . The present review focuses on the role of LPA and LPA receptors in epithelial inflammation and remodeling of the airway under normal and pathological conditions. .
Metabolism of LPA in airway epithelial cells
LPA synthesis can be intracellular or extracellular. Intracellular LPA synthesis involves at least two pathways, one mediated by phospholipase D (PLD) and phosphatidic acid (PA) specific phospholipase A (PLA) [19] ; and the other by acylglycerol kinase (AGK) [20, 21] . The existence of PLD/PLA pathway has been well demonstrated in several cell types; however, there is limited information on LPA generation in lung epithelial cells. LysoPLD or autotaxin contributes to extracellular LPA synthesis [22, 23] and lipid phosphate phosphatases (LPPs) are localized on the plasma membrane of cells [24, 25] and modulate extracellular LPA catabolism. This review will summarize recent studies regarding the role of AGK, lysoPLD, and LPPs in LPA metabolism in airways and their roles in airway biology.
Intracellular generation of LPA: role of AGK
While searching for sphingosine kinase isoforms, AGK was identified as a potential lipid kinase that generates intracellular LPA from monoacylglycerol (MAG) [20] . Immunofluorescence staining of lung epithelial cells revealed that AGK is localized to mitochondria [20, 21] and has limited activity on sphingosine or ceramide. Over-expression of AGK increased cellular LPA levels, while downregulation of AGK by using specific siRNA reduced cellular LPA levels [20, 21] . AGK-mediated intracellular LPA generation modulates the effects of exogenous LPA-induced activation of transcriptional factors and cytokine release [21, 26] . The mechanism by which intracellular LPA regulates cellular functions is not been well understood. Increase in PA level from intracellular LPA generation by over-expression of AGK may contribute to exogenous LPA-induced signaling and cellular functions. Down-regulation of AGK reduces histone acetylation thereby suggesting a role for AGK in regulating gene expression [26] . Since lung type II epithelial cells are rich in mitochondria, investigating the roles of AGK-mediated LPA and PA generation in the regulation of mitochondria functions in lung epithelial cells is likely to broaden our knowledge of mitochondria in inflammation.
Extracellular generation of LPA: role of lysoPLD
LPA levels in bronchoalveolar lavage (BAL) increase in lung inflammatory diseases, such as asthma [27, 28] , fibrosis [29] , and acute lung injury [16] . The mechanisms underlying the generation of LPA in BAL are still not clear; however, lysoPLD appears to contribute to BAL-LPA. LysoPLD, also referred to as autotaxin (ATX) or ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) is a key enzyme in plasma LPA generation from lysophosphatidylcholine (LPC). LysoPLD deficient mice die at embryonic day 8.5. On the other hand lysoPLD heterozygous mice appear healthy with just half the levels of plasma LPA [30] . It is widely expressed in mammalian tissues and abundantly present in blood. LPA production is attenuated in lysoPLD-depleted serum and plasma. In addition to blood, lysoPLD has been detected in other biological fluids such as cerebrospinal [31] . Lung epithelial cell expresses and release lysoPLD [4] . The lysoPLD substrate, lysoPC, is present in BAL fluid and is a part of the surfactant. Overexpression of lysoPLD or addition of recombinant lysoPLD to lung epithelial cells results in an increase in extracellular LPA levels and enhances cell migration [4] . These findings indicate that 1) BAL-LPA is generated from lysoPC by lysoPLD and 2) that autotaxin regulates cellular functions through LPA generation. Recent studies also demonstrate that autotaxin regulates cell motility by association with LPA receptor and integrins directly [4] .
Investigating the pathological role of lysoPLD in lung inflammatory diseases using lysoPLD transgenic and heterozygous knockout mice should provide the critical information required to develop therapeutic LPA targets to combat various pulmonary disorders.
Catabolism of LPA
LPA has a relatively short half-life (t 1/2 = ~2 h) in the cell culture media due to the presence of lipid phosphate phosphatases (LPPs) on the cell surface [32] . LPP family is comprised of three major isoforms, termed LPP1-3, which convert LPA to monoacylglycerol (MAG). LPPs are ecto-enzymes, which modulate LPA in circulation [25, 33] . LPPs dephosphorylate various lysophospholipids, including LPA and sphingosine-1-phosphate (S1P [32] . LPP1 deficient mice reduce LPA levels in multiple tissues by about 35 -95% thereby demonstrating that other LPPs may have a role in the breakdown of LPA [34] . Expression of LPPs in lung epithelial cells has been detected by RT-PCR and Western blotting. Over-expression of LPP-1 wild type increased LPA hydrolysis 2-3 fold over control and attenuated LPA-induced intracellular signaling and cytokine release in lung epithelial cells [32] . The relative contributions of this pathway in the regulation of LPA levels in airway epithelium need further investigation.
LPA increases IL-8 production in airway epithelium
Airway epithelium, the first line-of-defense to inhaled stimuli, including particulate matter, dust, allergens and various kinds of microbes, plays a protective role by enhancing its barrier integrity and releasing cytokines into the airway that chemo-attract immune cells [35, 36] . Interleukin (IL-8), a major neutrophil chemoattractant, plays an important role in innate immunity. LPA is potent stimulator of airway epithelial cells that triggers IL-8 gene expression [6, 15, 32, 37] . LPA increases IL-8 mRNA and protein release in a dose and a time dependent manner in human airway epithelial cells [6, 15] . Intratracheal injection of LPA into the mouse lungs stimulates MIP-2 (a murine analog of IL-8) levels in BAL fluid at 3 h and a significant infiltration of neutrophils into the airways at 6 h [6] . In comparison to LPA, LPS is a more powerful agonist and its effect on the induction of MIP-2 can be greater than 1000 fold. The significant differences between the effects of LPA and LPS indicate that exogenous LPA may have a protective effect in endotoxin-induced lung inflammation that was confirmed in later studies using either intratracheal [38] or intravenous [39, 40] routes for LPA administration. Thus, LPA plays a protective role towards infection by increasing transient innate immune responses in the early stage of inflammation.
LPA activates transcriptional factors
The LPA 1 production is not known. LPA mediated modulation of innate immunity in lungs therefore can be attributed to its ability to promote IL-8 generation.
Intracellular signaling regulates LPA-induced IL-8 production
LPA stimulates an increase in intracellular calcium levels [32] , phosphorylation of PKCδ [6] , and p38 MAPK [15, 16] , and activation of phospholipase D (PLD) [42, 43] . These signaling pathways regulate IL-8 production by modulating NF-κB activity [6, 32, 43] . LPA-induced phosphorylation of I-κB and IL-8 production were abolished by inhibition of these pathways using specific inhibitors or siRNA in lung epithelial cells [6, 32, 43] . LPA receptor activation is known to transactivate EGF-R through PKCδ-Lyn kinase-MMP2/3-mediated HB-EGF shedding [37] . The cross-talk between LPA receptors and EGF-R regulates LPA-induced IL-8 production, but not through activation of NF-κB and JNK/AP-1 pathways [37] . Since the cross-talk regulates C/EBPβ activity, C/EBPβ may be downstream of the cross-talk between the two receptors [41] , and thus contributes to IL-8 production. LPA-induced Erk pathway has no effect on IL-8 production as evidenced from studies using Erk inhibitor [41] . It will be interesting to be determine in vivo the cross-talk between LPA-Rs and EGF-R/PDGF-R in IL-8 secretion and recruitment of neutrophils into alveolar space and the physiological implications of such an interaction between G-protein coupled receptors and receptor tyrosine kinases in airway diseases.
LPA metabolizing enzymes regulate LPA-induced IL-8 production
LPA levels in tissues and cells are regulated by its conversion to PA by a long chain fatty acyl CoA: acyltransferase or to MAG by LPPs. LPP-1 regulates extracellular LPA levels by converting LPA to MAG [25, 32, 33] . Over-expression of LPP-1 enhanced exogenous LPA degradation and attenuated exogenous LPA-induced signaling, such as increases in intracellular calcium, phosphorylation of I-κB, and Erk, and IL-8 production in lung epithelial cells [32] . The mechanism of LPP-1 mediated regulation of LPA-induced signaling may be complex, since overexpression of LPP-1 (R217K) mutant partially attenuated LPA-induced IL-8 secretion without altering IL-8 mRNA levels [32] .
This result suggests that LPP-1 partly participates in LPA-induced cytokine secretion mechanism.
AGK regulates intracellular LPA levels by converting MAG to LPA [20, 21] . A recent study demonstrates that regulation of intracellular LPA by AGK modulates exogenous LPA-induced signaling and IL-8 production [21] . In addition to LPA receptors, PPARγ is an intracellular receptor of LPA [42] ; however, inhibition of PPARγ has no effect on LPA-induced IL-8 production (Zhao, Y. unpublished data) suggesting PPARγ-independent pathways regulate intracellular LPA-mediated IL-8 production in airway epithelial cells. Changes in AGK expression by plasmid overexpression or siRNA treatment modulate exogenous LPA-induced phosphorylation of p38 MAPK, I-κB, and EGF-R, which regulate IL-8 production [21] . However, how intracellular LPA regulates these pathways are still not clear. Inhibition of LPA receptors by PTx (pertussis toxin) attenuated AGK-mediated cell proliferation in PC-3 cells [20] . LPA receptors are not only localized on the cell surface, butalso exist in the cytoplasm and the nucleus [45] . The mechanisms of AGK-generated intracellular LPA mediated signal transduction and cellular responses need to be investigated in greater detail using different lung cells.
LPA regulates Th2 responses in airway epithelium
The relative balance between Th1 and Th2 responses plays a critical role in pathogenesis of lung inflammatory diseases. In addition to stimulating innate immunity, LPA regulates Th2 responses by increasing Th2 type cytokine decoy receptor [26, 42] and PGE2 release [46] in lung epithelial cells.
LPA-activated signaling and transcriptional factors contribute to these effects. Greater understanding of the above role of LPA in innate immunity is therefore crucial for the development of highly efficacious therapeutics with the least side effects.
LPA modulates IL-13/IL-13 receptor signal transduction
IL-13, a Th2 cytokine, plays a pivotal role in pathogenesis of bronchial asthma via IL-13 receptor alpha1 (IL-13Rα1) and IL-4 receptor alpha (IL-4Rα). Recent studies show that a decoy receptor for IL-13, namely IL-13α2, has higher binding efficiency to IL-13 and mitigates IL-13 signaling [47, 48] . Pretreatment with LPA attenuates IL-13-induced phosphorylation of STAT6 and cytokine release, suggesting an anti-inflammatory effect of LPA via attenuation of IL-13-induced inflammation [42] . LPA treatment induces IL-13Rα2 mRNA expression and protein release, without altering IL-13Rα1 and IL-4Rα expression, in lung epithelial cells. PLD-mediated JNK/AP-1 pathway, but not NF-κB pathway, regulates LPA-induced IL-13Rα2 expression [42] . The above study suggests a novel mechanism of regulation of IL-13Rα2 and IL-13 signaling that may be physiologically relevant to airway inflammation and remodeling.
LPA increases sST2 release
Soluble ST2 (sST2), an anti-inflammatory mediator, is known to function as a decoy receptor of IL-33 and attenuates IL-33-and endotoxin-induced inflammatory responses [49, 50] . LPA treatment increases sST2 mRNA expression and protein release in a dose and time dependent manner in lung epithelial cells [26] . The above effect of LPA is blocked by inhibition of LPA receptors. Both NF-κB and JNK/AP-1 pathways regulate LPA-induced sST2 release. In addition to activation of transcription factors, LPA treatment decreases histone deacetylase 3 (HDAC3) expression and enhances acetylation of histone H3 at lysine 9 that binds to the sST2 promoter region [26] .
Intracellular LPA generation by the AGK regulates exogenous LPA-induced histone H3 acetylation on sST2 promoter region, as well as sST2 gene expression [26] . sST2 treatment reduces LPSinduced cytokine release in macrophages. In lung epithelial cells, treatment with recombinant sST2 protein or sST2-rich cell culture media attenuates LPS-induced lung epithelial barrier disruption [26] . The above study unraveled a novel mechanism of exogenous LPA mediated regulation of Th2 cytokine decoy receptor, sST2, which plays an anti-inflammatory role in lung inflammatory diseases.
LPA increases COX2 expression and PGE2 release
LPA induces COX2 expression and PGE2 release in various cell types [51, 52] , including lung epithelial cells [41] . In the lung, COX-2 and PGE2 play an anti-inflammatory role, especially in Th2-dominant inflammation [53] . Transcriptional factors, NF-κB, JNK/AP-1, and C/EBPβ pathways regulate the effect of LPA [41] . Activation of C/EBPβ by EGFR is known to regulate expression of a variety of genes [54, 55] . Interestingly, only transcriptional activation of C/EBPβ, not NF-κB and JNK/AP-1, is regulated by the cross-talk between LPA receptors and EGFR in lung epithelial cells [41] . The transactivation of EGF-R by LPA is mediated by PLD2-activated PKCζ [41] . PGE2
induces biological functions through its receptors (EP1-4) on the surface of lung epithelial cells [56] .
The released PGE2 regulates particulate matter-induced IL-6 production [46] . In primary airway macrophages, PGE2 blocks IL-4/IL-13-induced eotaxin-2 release [57] . However, the role of PGE2/EP1-4 in IL-13Rα2 and sST2 production and release has not been investigated. It will be interesting to see whether COX-2/PGE2 plays a role in LPA-induced cytokine decoy receptor expression.
LPA in airway epithelial remodeling
The lung epithelial cells confer protection against environmental toxic injury by enhancing epithelial barrier integrity. LPA promote cellular motility through cytoskeleton rearrangement (ref).
LPA enhances airway epithelial barrier enhancement
Lung epithelial barrier integrity is maintained by cell-cell junctions. The adherens junction plays a critical role in regulating the activity of the entire junctional complex since the formation of the adherens junctions subsequently lead to the generation of other cell-cell junctions. LPA treatment enhances lung epithelial integrity through accumulation of E-cadherin at cell-cell contacts [38, 58] .
LPA-activates PKC isoforms, PKCδ and PKCζ, and FAK mediates E-cadherin accumulation at cellcell contacts [38, 58] . The direct role of these kinases on E-cadherin distribution at cell-cell junctions has not been investigated. However, c-Met, the receptor for HGF, interacts with Ecadherin at cell-cell contacts in response to LPA treatment, and PKCδ promotes c-Met serine phosphorylation and accumulation at cell-cell contacts [58] . These kinases may partly regulate Ecadherin localization through phosphorylation of c-Met, suggesting a potential role of c-Met in lung epithelial barrier integrity. The role of c-Met in lung epithelial barrier integrity and the underlying mechanisms could unravel novel therapeutic approaches to combat inflammatory lung diseases.
LPA induces lung epithelial cell migration
The migration of healthy lung epithelial cells to the injured site is a major mechanism of lung repair and remodeling that involves various intracellular cytoskeleton related proteins, including cortactin.
LPA treatment increases lung epithelial cell migration that is abolished by inhibition of PKCδ or abrogation of cortactin expression [4] . LPA induces tyrosine phosphorylation of cortactin on leading edge of migrating cell through activation of PKCδ [4] . LysoPLD, a key enzyme required for the generation of extracellular LPA, also regulates lung epithelial cell migration through LPA generation-dependent [4, 59] and independent pathways [4] . LysoPLD associates with LPA receptors and integrins on the cell surface, which induces cell migration. The association between lysoPLD and integrins has been demonstrated in platelets (60) . The mechanisms underlying tyrosine phosphorylation of cortactin via LPA mediated signaling are yet to be delineated. The underlying the tyrosine kinases could then be potential therapeutic targets with the advantage of readily available specific inhibitors.
LPA receptors in murine models of pulmonary inflammatory diseases
In contrast to exogenous LPA, the endogenous LPA appears to be a pro-inflammatory mediator.
LPA levels in BAL fluids are elevated in murine models of lung inflammatory diseases, including asthma [27, 28] , fibrosis [29] , and acute lung injury [16] . The increased LPA levels in these pathologies suggest that the rate of LPA generation is greater than the rate of its degradation. The chronically elevated levels of LPA in BAL fluid may trigger excess cytokine release and cell toxicity. Exogenous LPA on the other hand, has a relatively short half-life and induces a transient increase in neutrophils infiltration that modulates innate immunity and protects endotoxin-induced lung injury.
Endogenous LPA and LPA receptors in fibrosis
Pulmonary fibrosis is an inflammatory lung disorder characterized by abnormal formation and deposition of fibrous connective tissue proteins such as fibronectin and collagen in the lungs. In idiopathic pulmonary fibrosis subjects, LPA levels in BAL fluids are significantly elevated compared to normal healthy controls [29] . The source of LPA in BAL fluids has not been determined yet. In bleomycin challenged-murine model of fibrosis, LPA levels in BAL fluids significantly increased after 5 -10 days, while LPA 1 knockout mice offered significant resistance to bleomycin induced lung fibrosis [29] . Furthermore, Tager et al. demonstrated that LPA induces fibroblast proliferation, growth, and migration. TGFβ1, a multifunctional cytokine, plays a central role in pathogenesis of pulmonary fibrosis [29] . Recent studies show that LPA enhances TGFβ1 activation and apoptosis in lung epithelial cells [61] . LPA 1 is involved in LPA-induced apoptosis [61] , while LPA 2 contributes to TGFβ1 generation in lung epithelial cells [62] . Epithelialmesenchymal transition (EMT) plays a critical role in pathogenesis of fibrosis; however the role of LPA and LPA receptors in EMT has not been well investigated.
Endogenous LPA and LPA receptors in asthma
LPA levels are increased in BAL fluids from challenged asthmatic subjects, compared to unchallenged subjects, indicating that endogenous LPA may contribute to pathogenesis of asthma [27] . In a murine model of asthma, Schistosoma mansoni egg sensitization and challenge increased LPA levels in BAL fluids, eosinophil infiltration into airways and mucus production [28] . LPA 1 heterozygous mice however suffered from significantly reduced mucus production but not eosinophil infiltration, while LPA 2 heterozygous mice revealed a decrease in both eosinophil infiltration and mucus production [28] . These results suggest a pro-inflammatory role for endogenous LPA and LPA receptors in allergic asthma model. Recent study using OVA-challenged murine model of asthma demonstrated that LPA 2 deficient mice develop greater allergen-induced lung inflammation [63] . The opposing role of LPA 2 in modulating asthmatic lung inflammation may therefore be dependent on the expression levels of LPA receptors, allergens used to induce asthmatic phenotype in mice and severity of asthma.
Endogenous LPA and LPA receptors in acute lung injury
Elevated LPA levels in BAL fluids and plasma were detected LPS-induced murine model of acute lung injury [16] . LPA 1 knockout mice show decreased inflammation in LPS-induced acute lung injury; however, LPA levels in BAL fluids remain unaltered, compared to LPS challenged-wild type mice [16] . This suggests that genetic knockdown of LPA receptor in mice reduce inflammation, but not injury, mediated by LPS challenge. Furthermore, intratracheally administrated LPA 1&3 antagonist ki16425 reduced LPS-induced inflammatory cell infiltration and IL-6 levels in BAL, but had no effect on LPA level [16] . These data suggest that the endogenous LPA / LPA 1 -mediated cytokine release and neutrophil influx contribute to the pathogenesis of acute lung injury [16] .
Recent studies demonstrated that LPA 1 associates with CD14, a co-receptor of LPS. Inhibition of LPA 1 partly blocked LPS-induced signaling and IL-6 release in lung epithelial cells [16] . In addition, in THP-1 cells, either downregulation of lysoPLD or LPA 3 attenuated LPS-induced CCL8
release [64] . These studies suggest that LPA receptors are involved in LPS signaling. Future studies on LPS-induced LPA generation and degradation are necessary to understand the role of LPA and LPA receptors in acute lung injury.
Conclusion
In recent years, there has been overwhelming evidence in support of LPA and its receptors as key mediators of cell function under normal and pathological conditions. It is also becoming apparent that LPA signals not only extracellularly through its transmembrane G protein-coupled receptors on the cell surface but also intracellularly either directly or via its receptors that are localized on the nuclear membrane. Similar to other bioactive lipids such as S1P, LPA actions can be pro-or antiinflammatory depending upon the pathology of the disease and the underlying cell type(s).
LPA/LPAR mediated signaling also results in the transactivation of receptor tyrosine kinases such as 
